Company / Accounts Receivable
Travere Therapeutics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$80.1M
FY2025
5-year range
$15.9M / $80.1M
FY2021-FY2025
Trend
+195.5%
vs FY2024
Sector context
#63 of 113
Health Care
What the data says
At $80M, Travere Therapeutics, Inc.'s accounts receivable ranks #63 of 113 in the Health Care sector. Accounts Receivable has increased for 4 consecutive years, from $16M in FY2021 to $80M in FY2025.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of +38.1%.
Improved from $21M to $80M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +68.9%
- 5-Year CAGR
- +38.1%
- 10-Year CAGR
- -
Sector benchmark
#63 of 113 in Health CareTop 56% of 113This company $80.1M Sector average $1.1B
▼
-93.0% below sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s accounts receivable has grown for 4 consecutive years.
- 5-year CAGR of +38.1%, indicating consistent growth.
- In FY2025, accounts receivable increased 195.5% year-over-year.
- Ranks #63 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.1M | +195.5% |
| FY2024 | $27.1M | +28.0% |
| FY2023 | $21.2M | +27.2% |
| FY2022 | $16.6M | +4.6% |
| FY2021 | $15.9M | -0.1% |
| FY2020 | $15.9M | -11.8% |
| FY2019 | $18.0M | +24.6% |
| FY2018 | $14.5M | +4.5% |
| FY2017 | $13.9M | -25.1% |
| FY2016 | $18.5M | +48.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026